Herschorn S - Search Results

1

Effects of tolterodine extended release on patient perception of bladder condition and overactive bladder symptoms*.

Herschorn S, Heesakkers J, Castro-Diaz D, Wang JT, Brodsky M, Guan Z; Disease Management Study Team. Herschorn S, et al. Curr Med Res Opin. 2008 Dec;24(12):3513-21. doi: 10.1185/03007990802537122. Curr Med Res Opin. 2008. PMID: 19032133 Clinical Trial.

2

Impact of a health education intervention in overactive bladder patients.

Herschorn S, Becker D, Miller E, Thompson M, Forte L. Herschorn S, et al. Can J Urol. 2004 Dec;11(6):2430-7. Can J Urol. 2004. PMID: 15636668 Clinical Trial.

3

Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence.

Roehrborn CG, Abrams P, Rovner ES, Kaplan SA, Herschorn S, Guan Z. Roehrborn CG, et al. Among authors: herschorn s. BJU Int. 2006 May;97(5):1003-6. doi: 10.1111/j.1464-410X.2006.06068.x. BJU Int. 2006. PMID: 16643482 Clinical Trial.

4

A population-based study of urinary symptoms and incontinence: the Canadian Urinary Bladder Survey.

Herschorn S, Gajewski J, Schulz J, Corcos J. Herschorn S, et al. BJU Int. 2008 Jan;101(1):52-8. doi: 10.1111/j.1464-410X.2007.07198.x. Epub 2007 Oct 1. BJU Int. 2008. PMID: 17908260

5

Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers.

Chapple C, Herschorn S, Abrams P, Sun F, Brodsky M, Guan Z. Chapple C, et al. Among authors: herschorn s. Eur Urol. 2009 Sep;56(3):534-41. doi: 10.1016/j.eururo.2008.11.026. Epub 2008 Nov 24. Eur Urol. 2009. PMID: 19070418 Clinical Trial.

6

Efficacy and tolerability of fesoterodine in men with overactive bladder: a pooled analysis of 2 phase III studies.

Herschorn S, Jones JS, Oelke M, MacDiarmid S, Wang JT, Guan Z. Herschorn S, et al. Urology. 2010 May;75(5):1149-55. doi: 10.1016/j.urology.2009.09.007. Epub 2009 Nov 14. Urology. 2010. PMID: 19914702 Clinical Trial.

7

Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial.

Herschorn S, Swift S, Guan Z, Carlsson M, Morrow JD, Brodsky M, Gong J. Herschorn S, et al. BJU Int. 2010 Jan;105(1):58-66. doi: 10.1111/j.1464-410X.2009.09086.x. BJU Int. 2010. PMID: 20132103 Clinical Trial.

8

Tolerability of 5 mg solifenacin once daily versus 5 mg oxybutynin immediate release 3 times daily: results of the VECTOR trial.

Herschorn S, Stothers L, Carlson K, Egerdie B, Gajewski JB, Pommerville P, Schulz J, Radomski S, Drutz H, Barkin J, Paradiso-Hardy F. Herschorn S, et al. J Urol. 2010 May;183(5):1892-8. doi: 10.1016/j.juro.2010.01.012. Epub 2010 Mar 29. J Urol. 2010. PMID: 20303119 Clinical Trial.

9

Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo.

Chapple CR, Cruz F, Cardozo L, Staskin D, Herschorn S, Choudhury N, Stoelzel M, Heesakkers J, Siddiqui E. Chapple CR, et al. Among authors: herschorn s. Eur Urol. 2020 Jan;77(1):119-128. doi: 10.1016/j.eururo.2019.09.024. Epub 2019 Oct 18. Eur Urol. 2020. PMID: 31635815 Free article. Clinical Trial.

10

Safety and Tolerability Results from the PILLAR Study: A Phase IV, Double-Blind, Randomized, Placebo-Controlled Study of Mirabegron in Patients ≥ 65 years with Overactive Bladder-Wet.

Herschorn S, Staskin D, Schermer CR, Kristy RM, Wagg A. Herschorn S, et al. Drugs Aging. 2020 Sep;37(9):665-676. doi: 10.1007/s40266-020-00783-w. Drugs Aging. 2020. PMID: 32725584 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

291 results

Search Page

Filters